Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer

April 27, 2026 updated by: Yunnan Cancer Hospital
This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to provide a more accurate evidence for clinical diagnosis, promote the development of individualized treatment for gastric cancer, and ultimately improve the prognosis of patients.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

260

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Yunnan
      • Kunming, Yunnan, China
        • Yunnan Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • (a)Patients with gastric adenocarcinoma confirmed by histopathological biopsy and definite microsatellite status determined by immunohistochemistry (IHC);
  • (b)Abdominal dual-phase Quark CT scanning was performed within 2 weeks before surgery;
  • (c)aged ≥ 18 years old

Exclusion Criteria:

  • (a)Combined with other primary tumors;
  • (b) The image quality does not meet the diagnostic criteria;
  • (c)Those who cannot tolerate CT examination.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer
Medical images and clinical data related to gastric cancer were prospectively collected using a Philips Quark CT scanner, and its diagnostic accuracy and clinical application value in gastric cancer patients with different MSI statuses were evaluated to achieve accurate staging of gastric cancer. Patients diagnosed with gastric cancer at Yunnan Cancer Hospital from August 2025 to December 2026 were consecutively enrolled. After undergoing Philips Quark CT scanning, the N stage of gastric cancer was independently assessed by two radiologists, and statistical analysis was subsequently performed for the final results.
Diagnostic test: o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses
Abdominal CT scans were performed in addition to conventional treatment regimens

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pathological N stage
Time Frame: 1 day
The lymph node status confirmed by surgical pathology was used as the reference standard
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yunnan Cancer Hospital

Investigators

  • Study Director: Ye Lianhua, Study Director, Ethics Committee of Yunnan Provincial Cancer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 4, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

April 27, 2026

First Submitted That Met QC Criteria

April 27, 2026

First Posted (Actual)

May 4, 2026

Study Record Updates

Last Update Posted (Actual)

May 4, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KYLX2025-296

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Clinical Trials on o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe